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The Hospital for Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UKAbstractGiardia intestinalis is the commonest gastrointestinal protozoal pathogen worldwide, and causes acute and chronic diarrhoea with
malabsorption. First-line treatment is with a nitroimidazole, with a reported efﬁcacy rate of 89%. Failure of treatment can occur in
patients with hypogammaglobulinaemia or human immunodeﬁciency virus (HIV), or be due to nitroimidazole-resistant organisms. There is
little evidence to guide the clinical management of nitroimidazole-refractory disease. We performed a retrospective audit of
nitroimidazole-refractory giardiasis in returned travellers at the Hospital for Tropical Diseases, London between 2011 and 2013. Seventy-
three patients with microscopy-proven or PCR-proven giardiasis in whom nitroimidazole treatment had failed were identiﬁed, and their
management was investigated. In 2008, nitroimidazole treatment failed in 15.1% of patients. This increased to 20.6% in 2011 and to 40.2%
in 2013. Patient demographics remained stable during this period, as did routes of referral. Of patients with giardiasis, 39.0% had
travelled to India; this rose to 69.9% in patients with nitroimidazole-refractory disease. Of the patients with refractory disease, 44.6% had
HIV serological investigations performed and 36.5% had immunoglobulin levels determined. Patients with refractory disease were treated
with various agents, including albendazole, nitazoxanide, and mepacrine, alone or in combination. All 20 patients who received a
mepacrine-containing regimen were cured. This data shows a worrying increase in refractory disease, predominantly in travellers from
India, which is likely to represent increasing nitroimidazole resistance. Improved tools for the diagnosis of resistant G. intestinalis are
urgently needed to establish the true prevalence of nitroimidazole-resistant giardiasis, together with clinical trials to establish the most
effective second-line agent for empirical treatment regimens.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
Keywords: Albendazole, Giardia intestinalis, giardiasis, India, mepacrine, nitroimidazole, refractory, resistance, travellers
Original Submission: 14 January 2015; Revised Submission: 12 April 2015; Accepted: 27 April 2015
Editor: E. Bottieau
Article published online: 12 May 2015Corresponding author: L. E. B. Nabarro, The Hospital for Tropical
Diseases, Mortimer Market, Capper Street, London, WC1E 6JB, UK
E-mail: laura.nabarro@nhs.net
L. E. B. Nabarro and R. A. Lever are joint ﬁrst authors.IntroductionGiardia intestinalis is the commonest gastrointestinal protozoal
pathogen worldwide. It causes a spectrum of clinical disease,
ranging from asymptomatic carriage to acute or chronic diar-
rhoea with malabsorption. The commonest presentation inClinical Microbiology and Infection © 2015 European Society of Ctravellers is acute or chronic diarrhoea, which may be
accompanied by ﬂatulence and weight loss. Although giardiasis
is rarely life-threatening, chronic tiredness and gastrointestinal
symptoms may continue following eradication [1].
First-line treatment for giardiasis is using a nitroimidazole.
Metronidazole, 500 mg three times daily for one week, is
commonly used. The reported efﬁcacy is 89% [2]. Single-dose
tinidazole has similar efﬁcacy but fewer side effects, and thus
better compliance [2]. A study of 170 patients in Madrid be-
tween 1989 and 2004 found 5.8% failed a mean of 3 courses of
metronidazole [3]. Between 2007 and 2009, a study of travel-
lers returning to Barcelona found that nitroimidazole treatment
failed in 22% [4].Clin Microbiol Infect 2015; 21: 791–796
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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human immunodeﬁciency virus (HIV) [6], and coeliac disease.
Patients may become re-infected from a contaminated water
supply, an animal reservoir, or household or sexual contact.
G. intestinalis can become resistant to nitroimidazole treatment
and other antiprotozoal drugs [7].
The second-line treatment for patients in whom nitro-
imidazole treatment fails is unclear. Most drug efﬁcacy studies
have been conducted in treatment-naïve patients, and the re-
sults have been extrapolated to patients in whom nitro-
imidazole treatment has failed. A single randomized trial
investigated 20 patients in whom metronidazole treatment had
failed; of ten patients treated with albendazole, only two were
cured, in comparison with nine patients cured when albenda-
zole was combined with metronidazole [8]. Mørch evaluated a
treatment ladder for refractory giardiasis during a waterborne
outbreak in Norway [9]. Of 38 patients in whom metronidazole
treatment failed, 79% (30/38) were cured with 7 days of
combination metronidazole–albendazole. A further three of six
patients were cured with 7 days of paromomycin. The
remaining three were cured with combination quinacrine–
metronidazole for 2–3 weeks. All patients experienced
quinacrine-related side effects [9].
The Hospital for Tropical Diseases, London (HTD) is a
tertiary referral centre for tropical disease, and is part of
University College London Hospitals. An emergency self-
referral clinic is run daily for travellers returning from the
tropics with fever or diarrhoea. There are four general infec-
tious disease clinics a week, in which referrals are received
from general practitioners and hospitals around the UK. Diag-
nostic parasitological investigation is undertaken in the HTD
Department of Clinical Parasitology, which is also the Public
Health England National Parasitology Reference Laboratory.
Tinidazole is used as ﬁrst-line treatment for giardiasis in our
patients. Available second-line treatments include metronida-
zole, albendazole, paromomycin, nitazoxanide, and mepacrine
(quinacrine). These are given at the discretion of individual
clinicians.
In 2013, a number of clinicians at the HTD noticed an in-
crease in the number of patients with nitroimidazole-refractory
giardiasis. This audit aimed to establish whether the frequency
of nitroimidazole-refractory giardiasis was increasing in our
cohort, and the ways in which we were managing these
patients.Materials and methodsWe performed a retrospective audit of patients diagnosed
with giardiasis in 2008 and between the years 2011 andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect2013 at the HTD. Patients with parasitologically proven
giardiasis were identiﬁed from parasitology laboratory re-
cords of positive stool microscopy or PCR results. In 2008
and 2011, stool microscopy for cysts of G. intestinalis was
the only available method for diagnosis. In 2012, a multiplex
PCR, performed on stools, was introduced for the diagnosis
of G. intestinalis, Cryptosporidium and Entamoeba histolytica
infection. Thus, for 2012 and 2013, both stool microscopy
and PCR were performed on stool specimens from patients
with a queried diagnosis of giardiasis. Patients were
excluded if they had a previous diagnosis of giardiasis at the
HTD, or if they did not receive treatment for giardiasis at
the HTD.
Cases were deemed to be nitroimidazole refractory if they
fulﬁlled the following case deﬁnition: (a) patients referred to the
HTD with previously documented positive stool samples for
G. intestinalis, previous nitroimidazole treatment, and a positive
stool sample at the HTD at least 2 weeks following treatment;
or (b) patients reviewed at the HTD with a positive stool
sample for G. intestinalis at least 2 weeks after documented
nitroimidazole treatment.
Once refractory cases had been identiﬁed, further data were
collected from laboratory records, electronic letters, and case
notes. These included travel history and a complete history of
antiprotozoal treatment. If performed, immunoglobulin levels,
HIV status and coeliac status were recorded, together with re-
infection history.
Data were analysed with MS Excel 2010. Research approval
was not required, as this was an audit intended to document
current practice and improve future outcomes.ResultsBetween 2011 and 2013, 259 patients were diagnosed with
giardiasis; 179 were seen in the emergency clinic, and 39 were
referred from general practitioners. The source of referral was
unclear for 41 cases.
In 2008, nitroimidazole therapy failed in eight (15.1%) pa-
tients diagnosed with giardiasis. This increased to 15 (20.6%) in
2011, 23 (23.2%) in 2012, and 35 (40.2%) in 2013 (n = 259
cases) (Fig. 1).
In 2011, all patients diagnosed with giardiasis, either sensitive
or refractory to nitroimidazoles, were diagnosed by micro-
scopy. In 2012, 16 (28.6%) patients diagnosed with giardiasis by
microscopy had nitroimidazole-refractory giardiasis, as
compared with 14 (22.2%) diagnosed by PCR. In 2013, 21
(38.9%) patients diagnosed by microscopy had refractory giar-
diasis, as compared with 26 (47.3%) diagnosed by PCR
(Table 1).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 791–796
FIG. 1. Increasing rates of nitroimidazole-refractory giardiasis between 2008 and 2013. Only one sample per patient is included in this data.
TABLE 2. Sources of referral for patients with refractory
CMI Nabarro et al. Increased incidence of nitroimidazole-refractory giardiasis 793Of the patients with giardiasis, 39 (15.1%) were referred
from general practitioners. This remained stable between 2011
and 2013 (Table 2). The proportion of refractory patients was
consistently higher among external referrals (40.9%) than
among emergency clinic referrals (33.6%).
Of the patients with nitroimidazole-refractory disease, 51%
were female, with a mean age of 37 years. This remained
consistent between 2011 and 2013. Forty-four (60.2%)
received tinidazole as ﬁrst-line treatment and 29 (39.7%)
received metronidazole. Twenty-seven (36.5%) patients had
serum immunoglobulin (IgA, IgG, and IgM) levels determined,
and ﬁve (6.8%) of these had abnormal levels. Thirty-three
(44.6%) patients had an HIV test performed; two (2.7%) were
positive, but both patients were already known to have HIV.
Thirty (40.5%) patients had coeliac serological investigations
performed, but no new diagnoses were established. Only 15
(20.3%) patients were asked about risk factors for re-infection.
Between 2011 and 2013, 101 (39.0%) patients acquired
G. intestinalis in India, 42 (16.4%) elsewhere in Asia, and 47
(18.1%) in Africa. Travel history remained stable across years;TABLE 1. Refractory cases by diagnostic modality; the
increase in refractory disease is not an artefact of the
introduction of Giardia intestinalis PCR in 2011
2011 2012 2013
Microscopy alone 15 9 9
PCR alone 0 7 13
Microscopy and PCR 0 7 13
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyin 2011, 31 (42.5%) patients acquired G. intestinalis in India, as
compared with 37 (37.4%) in 2012 and 33 (37.9%) in 2013. In
contrast, of 73 nitroimidazole-refractory cases, 51 (69.9%) had
acquired G. intestinalis in India, ﬁve (6.8%) elsewhere in Asia, and
nine (12.3%) in Africa (Table 3).
Treatment strategies varied greatly between clinicians.
Common regimens included repeat tinidazole (typically 2 g as a
single dose), and tinidazole–albendazole combination treatment
and nitazoxanide (at varying doses). Mepacrine, alone or with
another agent, was used at 100 mg three times daily for a
median of 7 days (range 5–21 days). Table 4 shows the number
of clinical encounters in which a particular regimen was used,
and whether the patient required further treatment following
this. One hundred per cent of those receiving mepacrine-
containing regimens did not require further treatment.
Because of varying drug doses and lengths of treatment, we
were unable to analyse these data further. In total, six differentgiardiasis in 2011–2013, with numbers and percentages of
total and refractory cases, respectively
Sources 2011 2012 2013
Refractory cases, no. (%)
General practitioner 5 (33.3) 13 (56.5) 8 (22.9)
Emergency clinic 10 (66.7) 10 (43.5) 25 (71.4)
Other/unknown 0 (0) 0 (0) 2 (5.7)
All cases, no. (%)
General practitioner 9 (12.3) 19 (19.2) 11 (12.5)
Emergency clinic 50 (68.5) 65 (65.7) 64 (73.6)
Other/unknown 14 (19.2) 15 (15.2) 12 (13.8)
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 791–796
TABLE 3. Travel history of patients presenting with giardiasis
between 2011 and 2013 in comparison with those presenting
with nitroimidazole-refractory disease over the same period
Total cases Refractory cases
No. % No. %
India 101 39.0 51 69.9
Other Asia 42 16.2 5 6.8
Africa 47 18.1 9 12.3
Europe 5 1.9 2 2.7
Central/South America 17 6.6 1 1.4
No travel 18 6.9 4 5.5
Unknown 27 10.4 1 1.4
Middle East 1 0.4 0 0.0
North America 1 0.4 0 0.0
Total 259 100 73 100
794 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIdrugs were given alone or as combination therapy at a variety
of doses for different periods of time, giving a total of 11
different regimens.DiscussionThis study shows a rapid increase in the frequency of
nitroimidazole-refractory giardiasis in patients reviewed at the
HTD between 2008 and 2013. The reason for this is unclear.
Patient demographics have remained stable since 2008, as have
the countries in which giardiasis has been acquired. During this
time, we have continued to use 2 g of tinidazole as a single dose
as ﬁrst-line treatment, with no change in manufacturer or
administration.
In 2012, a multiplex protozoal PCR was introduced for the
diagnosis of giardiasis. This assay was developed and validated in
our laboratory. Although the sensitivity of this assay is unclear,TABLE 4. Agents used to treat refractory giardiasis between
2011 and 2013
Treatment
Total
treatment
episodes
Final
treatment
episodes
Patients who did
not require further
treatment at our
centre (%)
Tinidazole 39 23 58.9
Metronidazole 11 2 18.2
Albendazole 8 2 25
Nitazoxanide 18 9 50
Paromomycin 3 1 33.3
Mepacrine 11 11 100
Mepacrine and
albendazole
7 7 100
Mepacrine and
tinidazole
2 2 100
Tinidazole and
paromomycin
1 1 100
Tinidazole and
albendazole
20 12 60
Tinidazole and
nitazoxanide
2 1 50
Unclear 2 2 100
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectowing to the lack of an appropriate reference standard, it is
certainly more sensitive than stool microscopy. As PCR detects
DNA of G. intestinalis rather than intact cysts, it may be less
speciﬁc. However, stool samples are reportedly PCR negative 7
days post-treatment. In our cohort, the increase in refractory
disease was seen in patients diagnosed both by microscopy and
by PCR, and so is not an artefact of the introduction of PCR.
Similarly, between 2011 and 2013, the source of referral
remained stable. The proportion of patients with refractory
giardiasis was higher for external referrals than for emergency
clinic patients, probably because general practitioners initially
treat their patients with metronidazole, only referring if the
patient remains symptomatic.
Thus, we suspect that the increase in nitroimidazole-
refractory disease is due to increasing drug resistance. In vitro,
nitroimidazole resistance was demonstrated in 1988 by
exposing G. intestinalis to intermittent, slowly increasing con-
centrations of metronidazole [10]. This led to suggestions that
combination therapy should be used to avoid the development
of multidrug-resistant strains [11]. Despite this, demonstration
of nitroimidazole-resistant G. intestinalis in clinical specimens is
unusual [12]. It is hypothesized that nitroimidazole resistance is
associated with impaired mucosal attachment, and thus reduced
parasite ﬁtness [13].
There are several proposed mechanisms of nitroimidazole
resistance in G. intestinalis. The most thoroughly described hy-
pothesis is reduced pyruvate:ferredoxin oxidoreductase activity
[7]. Other possible resistance mechanisms may confer resis-
tance across several antiprotozoal classes; altered expression of
genes involved in the stress response may result in both
nitroimidazole and nitazoxanide resistance [14].
This increase in the frequency of nitroimidazole-refractory
giardiasis, which we think represents drug resistance, poses a
signiﬁcant clinical problem. Unlike bacterial diarrhoea, for
which the pathogen can be cultured and sensitivities obtained
within 48 h, G. intestinalis sensitivity testing cannot be per-
formed in most laboratories. The organism is difﬁcult and time-
consuming to culture, with a success rate of between 20% and
44% [15]. There are no established antimicrobial breakpoints,
and it is unclear whether in vivo response correlates with in vitro
sensitivity [5]. Although G. intestinalis has a fully sequenced
genome [16], and there is some understanding of the mecha-
nisms of nitroimidazole resistance, there are no known mo-
lecular markers for predicting drug resistance in clinical
specimens.
Seventy per cent of patients with refractory giardiasis had
travelled to India. This suggests that there is a signiﬁcant
amount of nitroimidazole-resistant giardiasis in India, although
there are no published data on resistance rates. There is evi-
dence of metronidazole resistance in other pathogens that areious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 791–796
CMI Nabarro et al. Increased incidence of nitroimidazole-refractory giardiasis 795commonly treated with nitroimidazoles, including Trichomonas
vaginalis [17] and Helicobacter pylori [18].
There is signiﬁcant overprescribing and overuse of antibi-
otics in healthcare in India, with a 40% increase in the amount of
antibiotics sold between 2005 and 2009 [19]. Factors driving
this include the sale of antibiotics without prescription, and
limited access to healthcare and microbiological services [20].
Lack of appropriate knowledge, the desire to meet patient
expectations, the fear of clinical failure and economic incentives
from drug companies may inﬂuence doctors to prescribe an-
tibiotics inappropriately [21].
Fixed-dose combinations containing ciproﬂoxacin and tini-
dazole are widely used in diarrhoea management. This is irra-
tional, as diarrhoea is usually caused by either bacteria or
protozoa, but not by both simultaneously [22]. Generic ﬁxed-
dose combinations usually contain 500 mg of ciproﬂoxacin
and 600 mg of tinidazole, taken twice daily. This gives an
adequate dose of ciproﬂoxacin, but falls short of the thera-
peutic dose of tinidazole (2 g once daily), potentially driving
drug resistance.
There is little evidence to guide the clinical management of
nitroimidazole-refractory giardiasis. Once nitroimidazole failure
has been parasitologically proven, we suggest investigating the
patient for risk factors for refractory disease, including immu-
noglobulin levels, HIV, and coeliac serology. This was per-
formed in only 36–45% of our patients. We also advocate
taking a detailed history to establish the risk of re-infection
from a household or sexual contact, water source, or infec-
ted animal.
Although the failure rate of nitroimidazole therapy in our
patient cohort is 40%, we continue to use single-dose tini-
dazole as ﬁrst-line treatment, because it is well tolerated,
with few contraindications to use. As second-line treatment,
we use 400 mg of albendazole twice daily for 7 days, with 2
g of tinidazole at the beginning and end of treatment. This is
based on Cacopardo’s small trial, which suggested synergism
between metronidazole and albendazole [8]. In addition, 60%
of patients given this combination in our cohort were cured.
If this fails, we offer 100 mg of mepacrine three times daily
for 7 days. The patient is counselled on the side effects of
mepacrine, notably a 0.4% risk of psychosis [23]. This
treatment is not offered to patients with a psychiatric his-
tory. During the period of this audit, 20 patients with
nitroimidazole-refractory giardiasis were treated with mepa-
crine; all were cured.
In our cohort of travellers, most of whom are well nourished
with no underlying disease and good access to healthcare, a 40%
ﬁrst-line antiprotozoal failure rate is inconvenient but not life-
threatening. In children in India, where the community preva-
lence can reach 30% [24], nitroimidazole resistance is moreClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyconcerning, as giardiasis is associated with long-term conse-
quences, including malnutrition and cognitive retardation [25].
Further work is needed to establish the prevalence of
nitroimidazole-resistant G. intestinalis in India. Simpliﬁed
methods for culture and sensitivity could allow routine testing
in clinical laboratories, and reduce the empirical treatment of
resistant disease. Genetic markers of resistance should be
sought to predict drug resistance in clinical isolates.
Until routine sensitivities are available in clinical practice,
empirical treatment of refractory disease will continue. Clinical
trials are needed to establish the most effective, affordable and
readily available second-line treatment. An observational, open-
label, multicentre study, GiardiaRef, has begun recruiting
through TropNet centres. The aim of this study is to assess the
clinical and parasitological efﬁcacy of combination chloro-
quine–albendazole vs. quinacrine (mepacrine) in patients in
whom nitroimidazole therapy has failed, and to evaluate
adverse effects and adherence as secondary outcomes [26].
Chloroquine is not widely used as a treatment for giardiasis.
Most data on its efﬁcacy come from small studies in children in
Cuba [27], and there is no evidence for its efﬁcacy in combi-
nation therapy or in patients with nitroimidazole-refractory
disease. A clinical trial of quinacrine (mepacrine) vs. tinida-
zole–albendazole combination therapy may be more relevant
and evidence based [8].
There are a number of limitations to our study. This was a
retrospective audit of case notes and electronic records, so
data quality was dependent on documentation. This did not
affect our understanding of treatment or tests for the under-
lying causes of refractory giardiasis. However, we suspect that
more patients were asked about risk factors for re-infection
than were documented. The absence of this data means that
we cannot exclude re-infection as a cause of treatment failure in
our refractory patients. We were unable to draw conclusions
about the efﬁcacy of individual drugs or combination therapy,
owing to the wide range of doses, courses and combinations
used. Furthermore, we did not routinely test for cure following
treatment, but relied on symptom resolution. Some patients
may have become asymptomatic carriers following treatment,
resulting in an underestimation of the prevalence of drug
resistance. In contrast, as giardiasis may be self-limiting, some
patients may have been cured despite, rather than because of,
treatment.ConclusionThis retrospective audit shows a worrying increase in the fre-
quency of nitroimidazole-refractory giardiasis, from 15% in
2008 to 40.3% in 2014. We suspect that this is due to increasingand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 791–796
796 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMInitroimidazole resistance in G. intestinalis, predominantly from
India. More work is essential to establish community resistance
rates in India. Improved tools for the diagnosis of resistant
G. intestinalis are urgently needed, together with clinical trials to
establish the most effective second-line agent for empirical
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